

# Kyowa Hakko Kirin Co., Ltd.

## Appendix to the Consolidated Financial Summary Fiscal 2015 Interim

(January 1, 2015 - June 30, 2015)

- This document was made as a supplement to the Kessan Tanshin (financial report), disclosed at the Tokyo Stock Exchange on July 31, 2015 for the interim of Fiscal 2015, the six-month period from January 1, 2015 to June 30, 2015.
- This document contains forward-looking statements based on a number of assumptions and beliefs held by management in light of information currently available. For a variety of reasons, actual financial results may differ materially from the forecasts presented here.
- Figures presented in this document have been rounded down to the nearest whole number.

Index	Page
I. Consolidated Financial Results	
1.Trends in consolidated income	1
2.Trends in results by segment	2
3.Other trends	3
II. Consolidated Balance Sheets	4
III. Consolidated Cash Flows	5
IV. Consolidated Subsidiaries and Affiliates	6
V. Kyowa Hakko Kirin Sales of Main Products	7
VI. Segment Information and Main Subsidiaries Operating Profit or Loss	
1.Pharmaceuticals segment	9
2.Bio-Chemicals segment	10
VII. R&D Pipeline	11

The average exchange rate for each period was as follows

Unit: yen

	2014 results				2015 results				2015 forecasts
	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Dec
US \$	103	103	103	105	119	120			120
EURO	141	141	140	140	138	135			133
GBP	171	171	171	173	183	183			181

<p>Contact            Kyowa Hakko Kirin Co., Ltd.            Corporate Communications Department            Tel 81 3 3282 0009</p>
--

## I. Consolidated Financial Results

### 1. Trends in consolidated income

Accumulative

Billions of yen, rounded down

	FY 2014 results				FY 2015 results								FY 2015 forecasts		
	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Mar	%	Jan - Jun	Change Amount	%	Jan - Sep	%	Jan - Dec	%	Jan - Dec	%
Net sales	86.0	161.8	238.9	333.4	89.5	104%	178.8	16.9	110%	-	-	-	-	360.0	108%
Gross Profit	51.2	98.2	146.5	205.9	51.9	101%	108.8	10.6	111%	-	-	-	-	-	-
Selling, general and administrative expenses	38.8	79.8	120.3	169.7	42.5	110%	86.3	6.5	108%	-	-	-	-	-	-
Operating income (prior to amortization of goodwill)	14.7	23.0	33.2	45.4	11.6	79%	27.0	4.0	118%	-	-	-	-	56.2	124%
Operating income	12.4	18.4	26.2	36.1	9.3	75%	22.4	4.0	122%	-	-	-	-	47.0	130%
Non-operating income	1.0	1.6	1.5	2.3	1.1	115%	1.8	0.2	117%	-	-	-	-	-	-
Non-operating expenses	1.3	3.1	4.0	8.9	2.4	174%	4.2	1.1	135%	-	-	-	-	-	-
Ordinary income	12.0	16.8	23.8	29.5	8.0	67%	20.0	3.2	119%	-	-	-	-	41.0	139%
Extraordinary income	0.3	0.3	0.3	0.3	0.6	201%	0.6	0.3	201%	-	-	-	-	-	-
Extraordinary loss	-	0.4	1.5	2.5	0.4	-	3.4	3.0	828%	-	-	-	-	-	-
Income before income taxes and minority interests	12.3	16.7	22.5	27.2	8.2	67%	17.2	0.4	103%	-	-	-	-	39.0	143%
Income taxes	6.0	7.5	10.5	11.3	3.6	61%	7.6	0.1	102%	-	-	-	-	-	-
Net income	6.3	9.1	12.0	15.8	4.6	73%	9.5	0.3	104%	-	-	-	-	26.0	164%
Comprehensive income	3.8	6.6	15.1	27.2	3.0	78%	14.2	7.5	213%	-	-	-	-	-	-
EPS prior to amortization of goodwill (¥/share)	15.80	25.24	34.67	45.95	12.65	80%	25.85	0.62	102%	-	-	-	-	64.41	140%

\* 1 "Prior to amortization of goodwill" refers to profits prior to the deduction of amortization of the goodwill arising on the reverse acquisition in April 2008 (Kirin Pharma share transfer).

(Note: This adjustment does not include goodwill amortization in respect of the acquisition of ProStrakan and others.)

\* 2 The FY 2015 forecasts are the revised forecasts announced on July 24, 2015.

### Quarterly

Billions of yen, rounded down.

	FY 2014 results				FY 2015 results								
	Jan - Mar	Apr - Jun	Jul - Sep	Oct - Dec	Jan - Mar	%	Apr - Jun	Change Amount	%	Jul - Sep	%	Oct - Dec	%
Net sales	86.0	75.8	77.0	94.5	89.5	104%	89.2	13.4	118%	-	-	-	-
Gross Profit	51.2	46.9	48.3	59.3	51.9	101%	56.9	10.0	121%	-	-	-	-
Selling, general and administrative expenses	38.8	40.9	40.5	49.4	42.5	110%	43.8	2.8	107%	-	-	-	-
Operating income (Prior to amortization of goodwill)	14.7	8.2	10.1	12.2	11.6	79%	15.4	7.1	187%	-	-	-	-
Operating income	12.4	5.9	7.8	9.8	9.3	75%	13.1	7.1	220%	-	-	-	-
Non-operating income	1.0	0.5	(0.0)	0.7	1.1	115%	0.7	0.1	119%	-	-	-	-
Non-operating expenses	1.3	1.7	0.8	4.9	2.4	174%	1.8	0.0	105%	-	-	-	-
Ordinary income	12.0	4.8	6.9	5.7	8.0	67%	11.9	7.1	250%	-	-	-	-
Extraordinary income	0.3	-	-	-	0.6	201%	-	-	-	-	-	-	-
Extraordinary loss	-	0.4	1.0	1.0	0.4	-	3.0	2.6	729%	-	-	-	-
Income before income taxes and minority interests	12.3	4.3	5.8	4.6	8.2	67%	8.9	4.5	204%	-	-	-	-
Income taxes	6.0	1.5	2.9	0.7	3.6	61%	4.0	2.4	262%	-	-	-	-
Net income	6.3	2.8	2.8	3.8	4.6	73%	4.9	2.0	172%	-	-	-	-
EPS prior to amortization of goodwill (¥/share)	15.80	9.44	9.44	11.28	12.65	80%	13.21	3.77	140%	-	-	-	-

## I. Consolidated Financial Results

### 2. Trends in results by segment

#### (1) Reported segment

Accumulative

Billions of yen, rounded down

	FY 2014 results				FY 2015 results								FY 2015 forecasts		
	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Mar	%	Jan - Jun	Change Amount	%	Jan - Sep	%	Jan - Dec	%	Jan - Dec	%
Net sales	86.0	161.8	238.9	333.4	89.5	104%	178.8	16.9	110%	-	-	-	-	360.0	108%
Pharmaceuticals	63.1	119.5	178.6	253.0	68.0	108%	135.3	15.8	113%	-	-	-	-	276.0	109%
Elimination of inter-segment sales	(0.2)	(0.5)	(0.8)	(1.1)	(0.2)	-	(0.4)	0.1	-	-	-	-	-	(1.0)	-
Bio-Chemicals	23.5	44.0	62.7	83.9	22.1	94%	45.0	0.9	102%	-	-	-	-	88.0	105%
Elimination of inter-segment sales	(0.3)	(1.1)	(1.6)	(2.4)	(0.3)	-	(1.0)	0.0	-	-	-	-	-	(3.0)	-
Operating income	12.4	18.4	26.2	36.1	9.3	75%	22.4	4.0	122%	-	-	-	-	47.0	130%
Before goodwill amortization	14.7	23.0	33.2	45.4	11.6	79%	27.0	4.0	118%	-	-	-	-	56.2	124%
Pharmaceuticals	9.4	14.1	20.6	29.0	7.7	83%	18.5	4.3	131%	-	-	-	-	38.5	132%
	11.5	18.4	27.0	37.6	9.9	86%	22.8	4.3	124%	-	-	-	-	47.1	125%
Bio-Chemicals	3.0	4.2	5.6	7.2	1.4	48%	3.9	(0.2)	95%	-	-	-	-	8.5	117%
	3.2	4.5	6.1	7.9	1.6	50%	4.3	(0.2)	95%	-	-	-	-	9.1	115%
Total	12.4	18.4	26.2	36.3	9.2	74%	22.5	4.1	123%	-	-	-	-	47.0	129%
	14.8	23.0	33.2	45.5	11.5	78%	27.1	4.1	118%	-	-	-	-	56.2	123%
Eliminations	(0.0)	0.0	(0.0)	(0.1)	0.0	-	(0.0)	(0.0)	-	-	-	-	-	-	-

#### Quarterly

Billions of yen, rounded down

	FY 2014 results				FY 2015 results								
	Jan - Mar	Apr - Jun	Jul - Sep	Oct - Dec	Jan - Mar	%	Apr - Jun	Change Amount	%	Jul - Sep	%	Oct - Dec	%
Net sales	86.0	75.8	77.0	94.5	89.5	104%	89.2	13.4	118%	-	-	-	-
Pharmaceuticals	63.1	56.3	59.1	74.3	68.0	108%	67.2	10.9	119%	-	-	-	-
Elimination of inter-segment sales	(0.2)	(0.2)	(0.2)	(0.2)	(0.2)	-	(0.2)	0.0	-	-	-	-	-
Bio-Chemicals	23.5	20.4	18.7	21.2	22.1	94%	22.8	2.4	112%	-	-	-	-
Elimination of inter-segment sales	(0.3)	(0.7)	(0.5)	(0.7)	(0.3)	-	(0.7)	0.0	-	-	-	-	-
Operating income	12.4	5.9	7.8	9.8	9.3	75%	13.1	7.1	220%	-	-	-	-
Before goodwill amortization	14.7	8.2	10.1	12.2	11.6	79%	15.4	7.1	187%	-	-	-	-
Pharmaceuticals	9.4	4.7	6.4	8.4	7.7	83%	10.7	6.0	227%	-	-	-	-
	11.5	6.8	8.5	10.6	9.9	86%	12.9	6.0	187%	-	-	-	-
Bio-Chemicals	3.0	1.1	1.4	1.6	1.4	48%	2.5	1.3	217%	-	-	-	-
	3.2	1.3	1.6	1.7	1.6	50%	2.6	1.3	203%	-	-	-	-
Total	12.4	5.9	7.8	10.0	9.2	74%	13.3	7.3	225%	-	-	-	-
	14.8	8.2	10.1	12.3	11.5	78%	15.6	7.3	190%	-	-	-	-
Eliminations	(0.0)	0.0	(0.0)	(0.1)	0.0	-	(0.1)	(0.2)	-	-	-	-	-

#### (2) Regional sales

Billions of yen, rounded down

	FY 2014 results								FY 2015 results							
	Jan - Mar	Percentage of consolidated sales	Jan - Jun	Percentage of consolidated sales	Jan - Sep	Percentage of consolidated sales	Jan - Dec	Percentage of consolidated sales	Jan - Mar	Percentage of consolidated sales	Jan - Jun	Percentage of consolidated sales	Jan - Sep	Percentage of consolidated sales	Jan - Dec	Percentage of consolidated sales
Japan sales	61.8	71.9%	115.7	71.5%	170.0	71.2%	239.2	71.7%	61.6	68.8%	122.8	68.7%	-	-	-	-
Overseas sales	24.2	28.1%	46.1	28.5%	68.8	28.8%	94.2	28.3%	27.9	31.2%	56.0	31.3%	-	-	-	-
America	5.5	6.4%	11.4	7.1%	16.5	6.9%	21.6	6.5%	7.4	8.3%	13.7	7.7%	-	-	-	-
Europe	11.0	12.8%	21.3	13.2%	32.6	13.7%	45.7	13.7%	13.2	14.8%	26.3	14.7%	-	-	-	-
Asia	7.3	8.5%	12.8	8.0%	19.0	8.0%	25.8	7.8%	7.0	7.9%	15.4	8.6%	-	-	-	-
Other regions	0.2	0.3%	0.4	0.3%	0.6	0.3%	0.9	0.3%	0.2	0.3%	0.4	0.3%	-	-	-	-
Total consolidated net sales	86.0	100%	161.8	100%	238.9	100%	333.4	100%	89.5	100%	178.8	100%	-	-	-	-

\* Sales classified by region or country based on location of customer.

## I. Consolidated Financial Results

### 3. Other trends

#### (1) R&D Expenses

Billions of yen, rounded down

	FY 2014 results				FY 2015 results				FY 2015 forecasts
	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Dec
R&D expenses	10.3	21.9	32.5	47.7	12.1	24.1	-	-	51.6
<i>R&amp;D to net sales ratio</i>	12.0%	13.5%	13.6%	14.3%	13.5%	13.5%	-	-	14.3%
Pharmaceuticals	9.5	20.2	30.0	44.0	11.3	22.5	-	-	48.2
<i>R&amp;D to net sales ratio</i>	15.2%	16.9%	16.8%	17.4%	16.7%	16.7%	-	-	17.5%
Bio-Chemicals	0.7	1.7	2.5	3.6	0.7	1.6	-	-	3.3

#### (2) Capital Expenditure (Property, plant and equipment)

Billions of yen, rounded down

	FY 2014 results				FY 2015 results				FY 2015 forecasts
	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Dec
Capital expenditure	5.3	12.1	20.9	27.2	5.6	10.2	-	-	22.0
Pharmaceuticals	2.8	6.5	11.5	14.8	2.2	4.6	-	-	11.8
Bio-Chemicals	2.4	5.5	9.4	12.4	3.3	5.6	-	-	10.2

#### (3) Depreciation Expenses (Property, plant and equipment and Intangible assets)

Billions of yen, rounded down

	FY 2014 results				FY 2015 results				FY 2015 forecasts
	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Dec
Depreciation and amortization expenses	5.2	10.8	16.9	23.8	5.5	11.2	-	-	22.7
<i>Amortization of intangible assets</i>	1.9	3.9	6.2	8.9	2.6	5.1	-	-	10.0
Pharmaceuticals	3.6	7.6	12.0	17.0	4.0	8.1	-	-	16.3
<i>Amortization of intangible assets</i>	1.9	3.8	6.2	8.8	2.6	5.1	-	-	10.0
Bio-Chemicals	1.5	3.2	4.8	6.8	1.4	3.0	-	-	6.4

\*Depreciation expenses for intangible assets do not include amortization of goodwill

#### (4) Amortization of Goodwill

Billions of yen, rounded down

	FY 2014 results				FY 2015 results				FY 2015 forecasts
	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Dec
Amortization expenses	3.0	6.0	9.3	12.8	3.3	6.6	-	-	13.3
<i>Reverse acquisition amortization of goodwill</i>	2.3	4.6	6.9	9.2	2.3	4.6	-	-	9.2
Pharmaceuticals	2.8	5.6	8.6	11.8	3.1	6.3	-	-	12.7
<i>Reverse acquisition amortization of goodwill</i>	2.1	4.3	6.4	8.6	2.1	4.3	-	-	8.6
Bio-Chemicals	0.2	0.4	0.6	0.9	0.1	0.3	-	-	0.6
<i>Reverse acquisition amortization of goodwill</i>	0.1	0.3	0.4	0.6	0.1	0.3	-	-	0.6

\*\*Reverse acquisition amortization of goodwill" refers to amortization of goodwill arising on the reverse acquisition in April 2008 (Kirin Pharma share transfer).

## II. Consolidated Balance Sheets

Billions of yen, rounded down

	2013	2014				2015				
	Dec 31	Mar 31	June 30	Sep 30	Dec 31	Mar 31	June 30	Change previous year end	Sep 30	Dec 31
<b>Assets</b>	<b>719.2</b>	<b>689.9</b>	<b>683.1</b>	<b>730.3</b>	<b>719.1</b>	<b>699.8</b>	<b>708.5</b>	<b>(10.5)</b>	-	-
Current assets	329.3	300.8	296.0	295.7	283.1	270.3	278.0	(5.1)	-	-
Cash and deposits	20.1	17.2	15.5	17.3	20.6	16.5	16.2	(4.3)	-	-
Notes and accounts receivable-trade	98.6	102.9	93.4	91.2	108.8	106.2	105.2	(3.6)	-	-
Inventories	75.7	78.9	79.9	90.3	91.2	91.5	90.2	(1.0)	-	-
Deferred tax assets	10.4	10.2	10.3	10.6	10.6	10.2	10.2	(0.3)	-	-
Short-term loans receivable	113.1	85.1	89.6	77.7	41.6	36.2	45.1	3.4	-	-
Other	11.2	6.3	7.1	8.3	10.0	9.4	10.8	0.7	-	-
Non-current assets	389.9	389.0	387.0	434.6	435.9	429.5	430.5	(5.3)	-	-
Property, plant and equipment	137.9	139.4	142.2	148.2	151.8	154.5	152.9	1.1	-	-
Buildings and structures	42.2	41.3	42.0	41.9	44.4	45.5	48.2	3.7	-	-
Machinery, equipment and vehicles	21.0	21.5	21.6	22.0	22.1	25.8	30.4	8.3	-	-
Land	54.6	54.5	54.4	54.2	54.2	54.0	51.0	(3.2)	-	-
Other	20.0	21.9	24.0	29.9	30.9	29.0	23.2	(7.7)	-	-
Intangible assets	212.0	207.6	203.0	241.5	241.5	228.9	230.6	(10.8)	-	-
Goodwill	163.7	161.6	158.8	169.5	173.2	165.7	166.0	(7.2)	-	-
Sales rights	46.5	44.3	42.8	70.4	67.2	62.3	63.8	(3.3)	-	-
Other	1.8	1.6	1.4	1.4	1.0	0.8	0.8	(0.2)	-	-
Investments and other assets	39.9	41.9	41.7	44.8	42.5	46.0	46.9	4.4	-	-
Investment securities	24.6	23.4	23.1	24.4	22.7	27.6	28.4	5.6	-	-
Net defined benefit asset	-	-	-	-	6.4	5.8	6.1	(0.3)	-	-
Deferred tax assets	3.8	3.9	3.9	5.5	8.0	7.1	7.0	(1.0)	-	-
Other	11.4	14.5	14.6	14.8	5.2	5.3	5.2	0.0	-	-
<b>Liabilities</b>	<b>123.8</b>	<b>98.4</b>	<b>88.8</b>	<b>134.4</b>	<b>113.7</b>	<b>100.0</b>	<b>97.5</b>	<b>(16.2)</b>	-	-
Current liabilities	85.0	76.7	67.2	108.3	85.1	76.4	74.6	(10.5)	-	-
Notes and accounts payable-trade	22.5	26.0	17.5	21.6	22.7	24.5	17.2	(5.5)	-	-
Short-term loans payable	6.2	4.8	5.7	4.8	4.8	4.9	4.8	(0.0)	-	-
Accounts payable-other	36.5	27.3	28.3	31.8	39.2	29.9	35.4	(3.7)	-	-
Income taxes payable	10.4	5.4	7.2	5.9	7.7	4.4	8.7	1.0	-	-
Provision	1.8	5.5	1.5	5.8	2.7	5.5	2.0	(0.6)	-	-
Other	7.4	7.5	6.6	38.2	7.8	7.0	6.1	(1.6)	-	-
Non-current liabilities	38.7	21.7	21.6	26.0	28.5	23.5	22.9	(5.6)	-	-
Deferred tax liabilities	11.8	11.3	11.3	15.8	16.2	14.5	13.8	(2.4)	-	-
Net defined benefit liability	-	-	-	-	3.7	2.0	2.0	(1.6)	-	-
Provision	22.9	6.4	6.3	6.4	3.4	3.4	3.3	(0.0)	-	-
Other	3.9	3.9	3.9	3.8	5.1	3.5	3.6	(1.5)	-	-
<b>Net assets</b>	<b>595.4</b>	<b>591.4</b>	<b>594.3</b>	<b>595.9</b>	<b>605.3</b>	<b>599.8</b>	<b>611.0</b>	<b>5.6</b>	-	-
Shareholders' equity	578.3	577.8	580.6	576.6	580.4	576.8	581.7	1.2	-	-
Capital stock	26.7	26.7	26.7	26.7	26.7	26.7	26.7	-	-	-
Capital surplus	512.3	512.3	512.3	512.3	512.3	509.1	509.1	(3.2)	-	-
Retained earnings	65.8	65.3	68.2	64.2	68.1	67.6	72.5	4.4	-	-
Treasury shares	(26.6)	(26.5)	(26.6)	(26.6)	(26.6)	(26.6)	(26.7)	(0.0)	-	-
Accumulated other comprehensive income	15.6	13.3	13.3	18.9	24.5	22.6	28.9	4.4	-	-
Valuation difference on available-for-sale securities	1.4	1.2	1.4	2.2	2.7	5.1	5.0	2.2	-	-
Foreign currency translation adjustment	14.2	12.1	11.8	16.7	24.4	20.1	26.4	2.0	-	-
Remeasurements of defined benefit plans	-	-	-	-	(2.6)	(2.6)	(2.4)	0.1	-	-
Subscription rights to shares	0.3	0.2	0.3	0.3	0.3	0.3	0.3	0.0	-	-
Minority interests	1.1	-	-	-	-	-	-	-	-	-
<b>Total liabilities and net assets</b>	<b>719.2</b>	<b>689.9</b>	<b>683.1</b>	<b>730.3</b>	<b>719.1</b>	<b>699.8</b>	<b>708.5</b>	<b>(10.5)</b>	-	-

### III. Consolidated cash flows

Billions of yen, rounded down

	2013	2014		2015		Breakdown
	Jan-Dec	Jan-Jun	Jan-Dec	Jan-Jun	Change	
<b>Cash flows from operating activities</b>	56.8	(0.5)	19.3	22.9	23.4	
Net income before taxes and minority interests	49.7	16.7	27.2	17.2	0.4	Net income 9.5 Tax expense 7.6
Accumulated depreciation expense	21.5	10.8	23.8	11.2	0.4	Property, plant and equipment 6.0 Intangible assets 5.1
Amortization of goodwill	11.5	6.0	12.8	6.6	0.5	Reverse acquisition amortization of goodwill 4.6 ProStrakan's goodwill 1.3
Increase (decrease) in working capital	(5.6)	(4.6)	(20.1)	(0.5)	4.1	Changes in notes and accounts receivables-trade 3.8 Changes in inventories 1.0 Changes in notes and accounts payable-trade (5.4)
Income taxes paid	(23.1)	(11.6)	(16.8)	(8.4)	3.2	
Other	2.7	(17.9)	(7.5)	(3.2)	14.6	
<b>Cash flows from investing activities</b>	(77.1)	1.6	16.8	(17.5)	(19.1)	
Purchase of property, plant and equipment	(21.5)	(16.3)	(30.4)	(9.8)	6.4	
Proceeds from sales of property, plant and equipment	1.7	0.1	0.1	0.0	(0.0)	
Purchase of intangible assets	(13.1)	(1.9)	(4.1)	(0.0)	1.9	
Purchase of investment securities	(3.8)	(1.1)	(4.5)	(5.2)	(4.0)	
Proceeds from sales of investment securities	3.9	0.0	1.2	0.0	0.0	
Proceeds from sales of shares of subsidiaries and associates	3.7	1.0	1.0	-	(1.0)	
Purchase of shares of subsidiaries resulting in change in scope of consolidation	-	-	(14.5)	-	-	
Net decrease (increase) in short-term loans receivable	(43.0)	20.4	68.3	(3.5)	(24.0)	Short-term loan receivable (exceeding 3 months) to Kirin Holdings
Other	(5.0)	(0.5)	(0.3)	1.0	1.5	
<b>Cash flows from financing activities</b>	(12.5)	(7.8)	(37.1)	(7.1)	0.7	
Net increase (decrease) in loans payable	0.0	(0.8)	(23.4)	(0.0)	0.8	
Purchase of treasury shares	(0.1)	(0.0)	(0.1)	(0.1)	(0.0)	
Cash dividends paid	(12.3)	(6.8)	(13.6)	(6.8)	0.0	
Other	(0.1)	(0.0)	0.0	(0.0)	(0.0)	
Effect of exchange rate change on cash and cash equivalents	1.7	(1.0)	(1.2)	(1.5)	(0.4)	
<b>Net increase (decrease) in cash and cash equivalents</b>	(31.0)	(7.8)	(2.2)	(3.2)	4.6	
Cash and cash equivalents at beginning of period	50.3	19.2	19.2	17.0	(2.2)	
<b>Cash and cash equivalents at end of period*</b>	19.2	11.4	17.0	13.8	2.3	

\*Cash and cash deposits in the consolidated balance sheet, cash and cash equivalents at end of period in consolidated cash flows, and cash reserves at end of period

<b>Cash and deposit accounts (consolidated balance sheet)</b>	20.1	15.5	20.6	16.2	0.7
Time deposits in excess of three months	(3.4)	(3.3)	(3.7)	(2.4)	0.8
Short-term loans receivable to the parent company not exceeding three months <sup>1</sup>	3.1	0.1	0.0	0.0	(0.1)
Current loans payable as negative cash equivalents (short-term loans payable)	(0.6)	(0.9)	-	-	0.9
<b>Cash and cash equivalents at end of period (consolidated cash flows)</b>	19.2	11.4	17.0	13.8	2.3
Time deposits in excess of three months	3.4	3.3	3.7	2.4	(0.8)
Short-term loans receivable to the parent company in excess of three months <sup>1</sup>	110.0	89.5	41.5	45.0	(44.5)
<b>Cash reserves at end of period</b>	132.6	104.2	62.2	61.2	(42.9)

<sup>1</sup> Based on cash management system (CMS) provided by our parent, Kirin Holdings, to each group company.

#### IV. Consolidated Subsidiaries and Affiliates

(As of June 30, 2015)

Segment	Type	Region	Company name	Percentage owned (direct and indirect)	Principal business
Pharmaceuticals	Consolidated subsidiary	Japan	Kyowa Medex Co., Ltd.	100.0%	Manufacture and sale of diagnostic reagents
			Kyowa Medical Promotion Co., Ltd.	100.0%	Promotion and sales of pharmaceuticals
			Chiyoda Kaihatsu Co., Ltd.	100.0%	Contracting, wholesale and retail and insurance agency business
		The Americas	Kyowa Hakko Kirin America, Inc.	100.0%	Supervision and management of subsidiaries (US)
			BioWa, Inc.	100.0%	Out-licensing of anti-body technology (US)
			Kyowa Hakko Kirin Pharma, Inc.	100.0%	Development of new candidate substances under contract (US)
			Kyowa Hakko Kirin California, Inc.	100.0%	Generation of new candidate substances under contract and accelerating research collaborations (US)
			ProStrakan Inc.	100.0%	Sales of pharmaceuticals (US)
			Archimedes Pharma US Inc.	100.0%	Licensing of pharmaceuticals (US)
		Europe	ProStrakan Group plc	100.0%	Supervision and management of special companies (UK)
			Strakan International S.a r.l.	100.0%	Sales, licensing-in and licensing-out of pharmaceuticals (UK)
			Strakan Pharmaceuticals Limited	100.0%	Development of pharmaceuticals (UK)
			ProStrakan Limited	100.0%	Sales of pharmaceuticals (UK)
			ProStrakan Pharma S.A.S *1	100.0%	Sales of pharmaceuticals (France)
			ProStrakan Farmaceutica SLU	100.0%	Sales of pharmaceuticals (Spain)
			ProStrakan Pharma GmbH *2	100.0%	Sales of pharmaceuticals (Germany)
			ProStrakan Holdings B.V.	100.0%	Holding company for subsidiaries (Netherlands)
			ProStrakan Pharma B.V.	100.0%	Sales of pharmaceuticals (Netherlands)
			ProStrakan S.r.l.	100.0%	Sales of pharmaceuticals (Italy)
			ProStrakan AB	100.0%	Sales of pharmaceuticals (Sweden)
			Archimedes Pharma Limited	100.0%	Supervision and management of subsidiaries (UK)
			Archimedes Development Limited	100.0%	Sales and development of pharmaceuticals (UK)
			Archimedes Holdings Limited	100.0%	Holding company for subsidiaries (UK)
			Archimedes Pharma Europe Limited	100.0%	Holding company for subsidiaries (UK)
			Archimedes Pharma UK Limited	100.0%	Sales of pharmaceuticals (UK)
		Archimedes Pharma Ibérica S.L.	100.0%	Sales of pharmaceuticals (Spain)	
		Archimedes Pharma Ireland Limited	100.0%	Sales of pharmaceuticals (Ireland)	
		Asia	Kyowa Hakko Kirin China Pharmaceutical Co., Ltd.	100.0%	Manufacture and sale of pharmaceuticals (China)
			Kyowa Hakko Kirin Korea Co., Ltd.	100.0%	Sales of pharmaceuticals (Korea)
			Kyowa Hakko Kirin (Taiwan) Co., Ltd.	100.0%	Sales of pharmaceuticals (Taiwan)
	Kyowa Hakko Kirin (Hong Kong) Co., Ltd.		100.0%	Sales of pharmaceuticals (Hong Kong)	
	Kyowa Hakko Kirin (Singapore) Pte. Ltd.		100.0%	Research and sale of pharmaceuticals (Singapore)	
	Entity accounted for using equity method	Japan	FUJIFILM KYOWA KIRIN BIOLOGICS Co., Ltd.	50.0%	Development, manufacture and sale of biosimilar pharmaceuticals
Bio-Chemicals	Consolidated subsidiary	Japan	Kyowa Hakko Bio Co., Ltd.	100.0%	Manufacture and sale of pharmaceutical and industrial raw materials, and health care products
			DAIICHI FINE CHEMICAL CO., LTD.*3	100.0%	Manufacture and sale of active pharmaceutical ingredients and pharmaceutical intermediates
			Kyowa Engineering Co., Ltd.	100.0%	Design and installation of plant facilities and equipment
		The Americas	BioKyowa Inc.	100.0%	Manufacture and sale of amino acids (US)
			Kyowa Hakko U.S.A., Inc.	100.0%	Sale of fine chemicals including amino acids (US)
			Kyowa Hakko Bio U.S. Holdings, Inc.	100.0%	Supervision and management of subsidiaries (US)
		Europe	Kyowa Hakko Europe GmbH	100.0%	Sale of fine chemicals including amino acids (Germany)
			Kyowa Hakko Bio Italia S.r.l.	100.0%	Sale of fine chemicals including amino acids (Italy)
		Asia	Shanghai Kyowa Amino Acid Co., Ltd.	100.0%	Manufacture and sale of amino acids (China)
			Thai Kyowa Biotechnologies Co., Ltd.	100.0%	Manufacture and sale of amino acids (Thailand)
			Kyowa Hakko (H.K.) Co., Ltd.	100.0%	Sale of fine chemicals including amino acids (Hong Kong)
			Kyowa Hakko Bio Singapore Pte. Ltd.	100.0%	Sale of fine chemicals including amino acids (Singapore)

Changes in scope of consolidation resulting in changes in subsidiaries (2015.1.1~2015.6.30)

New: None

Exclusions: 2: Archimedes Pharma France SAS (see note 1), Archimedes Pharma Germany GMBH (see note 2)

Notes:

1. On June 30, 2015, Archimedes Pharma France SAS was dissolved in a merger with ProStrakan Pharma S.A.S

2. On June 18, 2015, Archimedes Pharma Germany GMBH was dissolved in a merger with ProStrakan Pharma GmbH

3. On October 1, 2015, DAIICHI FINE CHEMICAL CO., LTD. is scheduled to change its company name (trade name) to "Kyowa Pharma Chemical Co., Ltd.



## V. Kyowa Hakko Kirin Sales of Main Products

Accumulative

Billions of yen, rounded down

	FY 2014 results				FY 2015 results								FY2015 forecasts		
	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Mar	%	Jan - Jun	Change amount	%	Jan - Sep	%	Jan - Dec	%	Jan - Dec	%
<b>Kyowa Hakko Kirin total</b>	52.1	97.0	143.1	201.7	53.8	103%	105.9	8.9	109%	-	-	-	-	215.7	107%
<b>Indication / Product name</b>															
<i>ESA formulation</i> <b>Nesp</b>	12.1	25.9	40.1	55.3	12.3	101%	27.0	1.1	105%	-	-	-	-	56.9	103%
<i>ESA formulation</i> <b>Espo</b>	0.6	1.2	1.8	2.4	0.4	71%	0.9	(0.3)	75%	-	-	-	-	1.8	77%
<i>Secondary hyperparathyroidism</i> <b>Regpara</b>	4.5	7.6	11.7	16.3	3.9	85%	8.5	0.9	112%	-	-	-	-	17.7	109%
<i>Secondary hyperparathyroidism</i> <b>Rocaltrol</b>	1.1	2.1	3.3	4.6	1.0	97%	2.4	0.2	113%	-	-	-	-	4.8	104%
<i>Type-2 diabetes</i> <b>Onglyza</b>	0.0	0.1	0.4	1.2	0.8	-	2.0	1.8	-	-	-	-	-	4.7	379%
<i>Cardiovascular (Hypertension &amp; angina pectoris)</i> <b>Coniel</b>	3.2	6.2	9.0	12.0	2.4	75%	5.0	(1.1)	81%	-	-	-	-	9.6	80%
<i>Cardiovascular (Hypertension)</i> <b>Coversyl</b>	0.7	1.4	2.1	2.8	0.5	81%	1.2	(0.2)	85%	-	-	-	-	2.4	84%
<i>Sustained-duration G-CSF</i> <b>G-Lasta</b>	-	-	-	0.3	1.4	-	3.8	3.8	-	-	-	-	-	8.9	-
<i>G-CSF</i> <b>Gran</b>	2.0	4.4	6.7	9.2	1.3	64%	2.8	(1.5)	65%	-	-	-	-	5.7	62%
<i>Transdermal persistent pain</i> <b>Fentos</b>	1.1	2.6	4.1	5.9	1.2	109%	2.8	0.2	109%	-	-	-	-	6.4	109%
<i>Anticancer</i> <b>Poteligeo</b>	0.2	0.6	1.1	1.5	0.4	183%	1.0	0.3	146%	-	-	-	-	2.0	132%
<i>Anticancer</i> <b>5-FU</b>	0.5	1.1	1.8	2.4	0.5	100%	1.1	0.0	101%	-	-	-	-	2.1	86%
<i>Anticancer</i> <b>Navelbine</b>	0.2	0.4	0.6	0.8	0.1	84%	0.3	(0.0)	86%	-	-	-	-	0.7	83%
<i>Chronic idiopathic thrombocytopenic purpura</i> <b>Romiplate</b>	0.5	1.2	1.9	2.7	0.6	109%	1.3	0.1	115%	-	-	-	-	2.8	105%
<i>Antiallergenic</i> <b>Allelock</b>	8.4	13.4	17.9	23.6	7.8	92%	12.4	(0.9)	93%	-	-	-	-	20.5	87%
<i>Antiallergic eyedrops</i> <b>Patanol</b>	7.1	8.1	9.9	11.8	7.4	105%	8.8	0.6	108%	-	-	-	-	11.9	101%
<i>Inflammatory bowel disease</i> <b>Asacol</b>	1.5	2.7	4.2	5.9	1.3	91%	2.9	0.1	107%	-	-	-	-	6.3	106%
<i>Psoriasis vulgaris</i> <b>Dovobet</b>	-	-	0.3	1.1	0.9	-	2.1	2.1	-	-	-	-	-	4.8	412%
<i>Parkinson's disease</i> <b>Nouria</b>	0.2	0.8	1.7	2.8	0.9	350%	2.2	1.3	263%	-	-	-	-	5.5	197%
<i>Antiepileptic</i> <b>Depakene</b>	2.3	4.6	6.9	9.4	2.0	88%	4.2	(0.3)	92%	-	-	-	-	8.7	93%
<i>Gastrointestinal</i> <b>Nauzelin</b>	1.0	1.9	2.7	3.8	0.8	84%	1.7	(0.2)	89%	-	-	-	-	3.5	90%
<b>Technology Out-Licensing</b>	2.0	4.1	6.4	13.9	1.7	82%	3.7	(0.4)	90%	-	-	-	-	12.8	92%

## V. Kyowa Hakko Kirin Sales of Main Products

Quarterly

Billions of yen, rounded down

	FY 2014 results				FY 2015 results								
	Jan - Mar	Apr - Jun	Jul - Sep	Oct - Dec	Jan - Mar	%	Apr - Jun	Change amount	%	Jul - Sep	%	Oct - Dec	%
<b>Kyowa Hakko Kirin total</b>	52.1	44.8	46.1	58.6	53.8	103%	52.1	7.2	116%	-	-	-	-
<b>Indication / Product name</b>													
<i>ESA formulation</i> <b>Nesp</b>	12.1	13.7	14.2	15.2	12.3	101%	14.7	1.0	108%	-	-	-	-
<i>ESA formulation</i> <b>Espo</b>	0.6	0.6	0.5	0.5	0.4	71%	0.5	(0.1)	79%	-	-	-	-
<i>Secondary hyperparathyroidism</i> <b>Regpara</b>	4.5	3.0	4.0	4.6	3.9	85%	4.6	1.5	151%	-	-	-	-
<i>Secondary hyperparathyroidism</i> <b>Rocaltrol</b>	1.1	1.0	1.1	1.3	1.0	97%	1.3	0.3	130%	-	-	-	-
<i>Type-2 diabetes</i> <b>Onglyza</b>	0.0	0.1	0.2	0.8	0.8	-	1.1	1.0	-	-	-	-	-
<i>Cardiovascular (Hypertension &amp; angina pectoris)</i> <b>Coniel</b>	3.2	2.9	2.8	3.0	2.4	75%	2.6	(0.3)	88%	-	-	-	-
<i>Cardiovascular (Hypertension)</i> <b>Coversyl</b>	0.7	0.7	0.6	0.7	0.5	81%	0.6	(0.0)	88%	-	-	-	-
<i>Sustained-duration G-CSF</i> <b>G-Lasta</b>	-	-	-	0.3	1.4	-	2.4	2.4	-	-	-	-	-
<i>G-CSF</i> <b>Gran</b>	2.0	2.3	2.3	2.4	1.3	64%	1.5	(0.7)	66%	-	-	-	-
<i>Transdermal persistent pain</i> <b>Fentos</b>	1.1	1.4	1.5	1.7	1.2	109%	1.5	0.1	108%	-	-	-	-
<i>Anticancer</i> <b>Poteligeo</b>	0.2	0.4	0.4	0.4	0.4	183%	0.5	0.1	126%	-	-	-	-
<i>Anticancer</i> <b>5-FU</b>	0.5	0.6	0.6	0.6	0.5	100%	0.6	0.0	101%	-	-	-	-
<i>Anticancer</i> <b>Navelbine</b>	0.2	0.2	0.2	0.2	0.1	84%	0.1	(0.0)	88%	-	-	-	-
<i>Chronic idiopathic thrombocytopenic purpura</i> <b>Romiplate</b>	0.5	0.6	0.7	0.7	0.6	109%	0.7	0.1	120%	-	-	-	-
<i>Antiallergenic</i> <b>Allelock</b>	8.4	4.9	4.5	5.6	7.8	92%	4.6	(0.3)	93%	-	-	-	-
<i>Antiallergic eyedrops</i> <b>Patanol</b>	7.1	1.0	1.7	1.9	7.4	105%	1.3	0.2	124%	-	-	-	-
<i>Inflammatory bowel disease</i> <b>Asacol</b>	1.5	1.2	1.5	1.7	1.3	91%	1.5	0.3	128%	-	-	-	-
<i>Psoriasis vulgaris</i> <b>Dovobet</b>	-	-	0.3	0.8	0.9	-	1.2	1.2	-	-	-	-	-
<i>Parkinson's disease</i> <b>Nouriastr</b>	0.2	0.5	0.8	1.1	0.9	350%	1.2	0.7	221%	-	-	-	-
<i>Antiepileptic</i> <b>Depakene</b>	2.3	2.3	2.2	2.4	2.0	88%	2.2	(0.1)	95%	-	-	-	-
<i>Gastrointestinal</i> <b>Nauzelin</b>	1.0	0.9	0.8	1.1	0.8	84%	0.8	(0.0)	95%	-	-	-	-
<b>Technology Out-Licensing</b>	2.0	2.0	2.2	7.5	1.7	82%	2.0	(0.0)	97%	-	-	-	-

## VI. Segment information and Main Subsidiaries Operating Profit or Loss

### 1. Pharmaceuticals segment

#### (1) Pharmaceuticals segment total

Billions of yen, rounded down

	FY 2014 results				FY 2015 results								FY 2015 forecasts		
	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Mar	%	Jan - Jun	Change Amount	%	Jan - Sep	%	Jan - Dec	%	Jan - Dec	%
Net sales	63.1	119.5	178.6	253.0	68.0	108%	135.3	15.8	113%	-	-	-	-	276.0	109%
Japan sales	49.6	92.3	137.3	195.1	50.0	101%	100.1	7.8	108%	-	-	-	-	201.8	103%
Overseas sales	13.5	27.2	41.3	57.8	17.9	133%	35.1	7.9	129%	-	-	-	-	74.1	128%
America	3.4	7.2	10.3	13.4	4.8	140%	8.4	1.2	117%	-	-	-	-	13.8	103%
Europe	6.8	13.2	20.6	30.0	8.9	130%	18.1	4.8	137%	-	-	-	-	42.4	141%
Asia and others	3.1	6.6	10.4	14.3	4.1	130%	8.5	1.9	128%	-	-	-	-	17.8	124%
Operating income	9.4	14.1	20.6	29.0	7.7	83%	18.5	4.3	131%	-	-	-	-	38.5	132%

#### (2) ProStrakan (GBP)

Millions of GBP, rounded down

	FY 2014 results				FY 2015 results								FY 2015 forecasts		
	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Mar	%	Jan - Jun	Change Amount	%	Jan - Sep	%	Jan - Dec	%	Jan - Dec	%
Net sales	38.4	78.0	125.3	181.4	53.7	140%	108.7	30.6	139%	-	-	-	-	220.1	121%
Cancer pain <b>Abstral</b>	12.1	25.7	40.6	55.8	12.9	107%	27.5	1.7	107%	-	-	-	-	56.2	101%
Cancer pain <b>PecFent</b>	-	-	2.4	7.5	5.4	-	10.9	10.9	-	-	-	-	-	24.3	323%
Chemotherapy-induced nausea and vomiting drug <b>Sancuso</b>	2.7	6.3	10.0	14.0	3.9	140%	8.2	1.9	131%	-	-	-	-	18.2	130%
Replacement therapy with testosterone for male hypogonadism <b>Tostran</b>	2.7	5.9	9.2	13.0	5.8	216%	9.2	3.2	154%	-	-	-	-	16.1	123%
Relief of pain associated with chronic anal fissures <b>Rectogesic</b>	2.7	5.6	8.4	11.5	2.8	102%	5.4	(0.2)	96%	-	-	-	-	10.6	92%
Osteoporosis drug <b>Adcal-D3</b>	7.1	13.9	21.3	29.3	6.7	94%	13.2	(0.6)	95%	-	-	-	-	27.8	95%
<b>Others</b>	7.9	15.3	27.9	44.4	15.7	199%	32.5	17.1	212%	-	-	-	-	64.8	146%
Product net sales (subtotal)	35.4	72.9	120.0	175.9	53.4	151%	107.2	34.2	147%	-	-	-	-	218.3	124%
<b>Technology Out-Licensing and others</b>	2.9	5.0	5.2	5.4	0.2	8%	1.4	(3.6)	29%	-	-	-	-	1.8	33%
Gross profit	28.8	58.7	91.0	129.1	38.9	135%	81.4	22.6	139%	-	-	-	-	161.7	125%
Selling, general and administrative expenses *1	17.8	35.2	55.0	80.0	22.5	126%	45.1	9.9	128%	-	-	-	-	91.0	114%
EBIDTA *2	10.9	23.5	35.9	49.1	16.4	150%	36.2	12.7	154%	-	-	-	-	70.7	144%
Amortization of goodwill and sales rights *1	9.9	19.9	33.2	49.2	15.4	155%	30.6	10.7	154%	-	-	-	-	61.9	126%
Operating income	1.0	3.5	2.6	(0.1)	1.0	105%	5.6	2.0	156%	-	-	-	-	8.7	-

\*1 Amortization of goodwill and sales rights is not included in Selling, general and administrative expenses

Amortization of goodwill and sales rights= Depreciation + amortization of goodwill

\*2 EBITDA=Operating income + depreciation + amortization of goodwill

\*3 Archimedes was acquired by ProStrakan on August 5, 2014, and from August 2014, Archimedes' financial results have been consolidated with those of ProStrakan.

\*4 Geographical breakdown of sales for January - June 2015 is as follows:

UK	Europe (excluding UK)	USA	Other
31.7%	49.8%	16.7%	1.8%

#### (3) Kyowa Medex Co., Ltd.

Billions of yen, rounded down

	FY 2014 results				FY 2015 results								FY 2015 forecasts		
	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Mar	%	Jan - Jun	Change Amount	%	Jan - Sep	%	Jan - Dec	%	Jan - Dec	%
Net sales	2.6	5.7	8.4	11.7	2.5	95%	5.5	(0.1)	98%	-	-	-	-	11.9	101%
Japan sales	2.1	4.6	7.0	9.7	2.1	99%	4.6	(0.0)	100%	-	-	-	-	10.0	103%
Biochemical Diagnostic Reagent	0.8	1.9	2.9	4.0	0.8	99%	1.8	(0.0)	99%	-	-	-	-	4.0	101%
Immunological Diagnostic Reagent	1.0	2.3	3.4	4.7	0.9	94%	2.2	(0.0)	98%	-	-	-	-	4.8	102%
Other	0.2	0.4	0.6	0.8	0.2	115%	0.4	0.0	110%	-	-	-	-	1.0	118%
Exports	0.5	1.0	1.4	2.0	0.4	80%	0.9	(0.0)	91%	-	-	-	-	1.8	93%
Operating income	0.0	0.3	0.4	0.7	0.0	83%	0.3	(0.0)	93%	-	-	-	-	0.9	126%

## VI. Segment information and Main Subsidiaries Operating Profit or Loss

### 2. Bio-Chemicals segment

#### (1) Bio-Chemicals segment total

Billions of yen, rounded down

	FY 2014 results				FY 2015 results								FY 2015 forecasts		
	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Mar	%	Jan - Jun	Change Amount	%	Jan - Sep	%	Jan - Dec	%	Jan - Dec	%
Net sales	23.5	44.0	62.7	83.9	22.1	94%	45.0	0.9	102%	-	-	-	-	88.0	105%
Japan sales	12.9	25.1	35.2	47.6	12.1	94%	24.1	(0.9)	96%	-	-	-	-	48.5	102%
Overseas sales	10.6	18.8	27.4	36.3	10.0	94%	20.8	1.9	110%	-	-	-	-	39.5	109%
America	2.0	4.1	6.2	8.2	2.5	124%	5.2	1.1	127%	-	-	-	-	9.9	119%
Europe	4.1	8.0	12.0	15.6	4.3	103%	8.2	0.1	102%	-	-	-	-	15.0	96%
Asia and others	4.4	6.6	9.2	12.4	3.1	71%	7.3	0.6	110%	-	-	-	-	14.6	118%
Operating income	3.0	4.2	5.6	7.2	1.4	48%	3.9	(0.2)	95%	-	-	-	-	8.5	117%

#### (2) Kyowa Hakko Bio Co., Ltd.

Billions of yen, rounded down

	FY 2014 results				FY 2015 results								FY 2015 forecasts		
	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Mar	%	Jan - Jun	Change Amount	%	Jan - Sep	%	Jan - Dec	%	Jan - Dec	%
Net sales	17.3	31.5	44.5	58.0	14.1	82%	31.0	(0.4)	99%	-	-	-	-	61.4	106%
Japan sales	9.9	19.1	27.1	35.7	8.7	89%	18.1	(0.9)	95%	-	-	-	-	36.4	102%
Pharmaceutical and industrial materials	4.2	8.1	11.4	14.9	3.2	76%	6.9	(1.2)	85%	-	-	-	-	13.9	94%
Healthcare	2.6	5.4	8.2	11.0	2.5	96%	5.6	0.2	105%	-	-	-	-	12.1	110%
Other	2.9	5.5	7.5	9.8	2.9	100%	5.5	0.0	100%	-	-	-	-	10.3	106%
Exports	7.4	12.3	17.3	22.3	5.4	73%	12.9	0.5	104%	-	-	-	-	25.0	112%
Operating income	2.7	3.6	4.7	5.6	1.3	48%	2.9	(0.6)	81%	-	-	-	-	6.2	111%

#### (3) DAIICHI FINE CHEMICAL CO., LTD.





Billions of yen, rounded down

	FY 2014 results				FY 2015 results								FY 2015 forecasts		
	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Mar	%	Jan - Jun	Change Amount	%	Jan - Sep	%	Jan - Dec	%	Jan - Dec	%
Net sales	3.5	6.9	9.4	13.3	3.5	100%	6.6	(0.3)	96%	-	-	-	-	13.3	100%
Operating income	(0.0)	(0.0)	(0.1)	0.3	0.1	-	0.7	0.8	-	-	-	-	-	1.7	458%













VII. R&D Pipeline



Filed • Approved  antibody  protein  small molecule

As of Jul. 24, 2015

Area		Code Name Generic Name Formulation	Mechanism of Action	Indication	Stage	In-House or Licensed	Remarks
Nephrology		<b>KRN321</b> <b>Darbepoetin Alfa</b> <b>Injection</b>	Long-Acting Erythropoiesis Stimulating Agent	Renal Anemia (on Dialysis)	Filed in CN	Kirin-Amgen	
Oncology		<b>Granisetron</b> <b>Patch</b>	5-HT <sub>3</sub> Serotonin Receptor Antagonist	Chemotherapy induced Nausea and Vomiting	NDA in preparation in MY	Licensed from Solasia Pharma (ProStrakan)	Launched by ProStrakan as Sancuso®
Other		<b>©KW-3357</b> <b>Antithrombin Gamma</b> <b>Injection</b>	Recombinant Human Antithrombin	Disseminated Intravascular Coagulation, Congenital Antithrombin Deficiency	Approved in JP	In-House	
		<b>AMG531</b> <b>Romiplostim</b> <b>Injection</b>	Thrombopoietin Receptor Agonist	Idiopathic (Immune) Thrombocytopenic Purpura	Approved in TW and HK Filed in KR and TH NDA in preparation in MY	Kirin-Amgen	

Phase II, Phase III









Area		Code Name Generic Name Formulation	Mechanism of Action	Indication	Stage	In-House or Licensed	Remarks
Nephrology		<b>©RTA 402</b> <b>Bardoxolone Methyl</b> <b>Oral</b>	Antioxidant Inflammation Modulator	CKD in Patients with Type 2 Diabetes	Phase II in JP	Licensed from Reata	
		<b>©KHK7580</b> <b>Oral</b>	Calcium Receptor Agonist	Secondary Hyperparathyroidism	Phase II in JP	Licensed from Mitsubishi Tanabe Pharma	
Oncology		<b>©ARQ 197</b> <b>Tivantinib</b> <b>Oral</b>	c-Met Inhibitor	Hepatocellular Cancer	Phase III in JP	Licensed from ArQule	
		<b>©BW-8962</b> <b>Injection</b>	Anti-GM2 Humanized Antibody	Cancer	Phase I / IIa in KR	In-House	POTELLIGENT®
		<b>KW-0761</b> <b>Mogamulizumab</b> <b>Injection</b>	Anti-CCR4 Humanized Antibody	Peripheral T-cell Lymphoma Adult T-cell Leukemia/Lymphoma Cutaneous T-cell Lymphoma	Phase II in EU Phase II in US, EU and others Phase III in US, EU, JP and others	In-House	POTELLIGENT®
Immunology/ Allergy		<b>©KHK4563</b> <b>Benralizumab</b> <b>Injection</b>	Anti-IL-5 Receptor Humanized Antibody	Asthma Chronic Obstructive Pulmonary Disease(COPD)	Phase III in JP and KR Phase III in JP	In-House	Jointly Developed with AstraZeneca/MedImmune in JP and KR POTELLIGENT®
		<b>©ASKP1240</b> <b>Injection</b>	Anti-CD40 Fully Human Antibody	Organ Transplant Rejection	Phase I in JP Phase II in US	In-House	Jointly Developed with Astellas KM mouse
		<b>Z-206</b> <b>Mesalazine</b> <b>Oral</b>	pH Dependent Controlled Release Tablet	Ulcerative Colitis	Phase III in JP	Licensed from Zeria Pharma	Jointly Developed with Zeria Pharma The Phase III study is conducted to seek a new dose regimen
		<b>©KHK4827</b> <b>Brodalumab</b> <b>Injection</b>	Anti-IL-17 Receptor Fully Human Antibody	Psoriasis	Phase III in JP	Kirin-Amgen	
Central Nervous System		<b>KW-6002</b> <b>Istradefylline</b> <b>Oral</b>	Adenosine A <sub>2A</sub> Receptor Antagonist	Parkinson's Disease	Phase III in US, CA, EU and others	In-House	
Other		<b>©KRN23</b> <b>Injection</b>	Anti-FGF23 Fully Human Antibody	X-linked Hypophosphatemia (XLH) in adult patients X-linked Hypophosphatemia (XLH) in pediatric patients Tumor Induced Osteomalacia (TIO)/Epider mal Nevus Syndrome (ENS)	Phase II in US Phase I in JP and KR Phase II in US and EU Phase II in US	In-House	Jointly Developed with Ultragenyx in US and EU KM mouse
		<b>AMG531</b> <b>Romiplostim</b> <b>Injection</b>	Thrombopoietin Receptor Agonist	Aplastic Anemia	Phase II in KR	Kirin-Amgen	



 Updated since Apr 21st, 2015 (Area, Stage, Filed, Approved, etc.)  
 New Molecular Entity

VII. R&D Pipeline

Ph I  antibody  protein  small molecule



As of Jul. 24, 2015

Area		Code Name Generic Name Formulation	Mechanism of Action	Indication	Stage	In-House or Licensed	Remarks
Oncology		©KRN951 Tivozanib Oral	VEGF Receptor Inhibitor	Cancer	Phase I in JP	In-House	Being Developed overseas by AVEO as AV-951
		©KHK2898 Injection	Anti-CD98 Fully Human Antibody	Cancer	Phase I in SG	In-House	POTELLIGENT® KM mouse
		©KHK2823 Injection	Anti-CD123 Fully Human Antibody	Cancer	Phase I in UK	In-House	POTELLIGENT® KM mouse
		©KHK2804/ CEP-37250 Injection	Anti-Tumor Specific Glycoprotein Humanized Antibody	Cancer	Phase I in US	Licensed from Teva	Jointly Developed with Teva POTELLIGENT®
		KW-0761 Mogamulizumab Injection	Anti-CCR4 Humanized Antibody	Solid Tumor	Phase I in US  Phase I in JP	In-House	Combination with MED14736/tremelimumab (Jointly Developed with AstraZeneca) POTELLIGENT® Combination with Docetaxel POTELLIGENT® Combination with PF- 05082566 (Jointly Developed with Pfizer) POTELLIGENT® Combination with nivolumab (Jointly Developed with Ono Pharmaceutical / Bristol-Myers Squibb) POTELLIGENT®
Immunology/ Allergy		©KHK4083 Injection	Immunomodulator Antibody	Autoimmune diseases	Phase I in CA	In-House	POTELLIGENT® KM mouse
Central Nervous System		©KHK6640 Injection	Anti-Amyloid Beta Peptide Antibody	Alzheimer's Disease	Phase I in EU Phase I in JP	Licensed from Immunas Pharma	
Others		©KW-3357 Antithrombin Gamma Injection	Recombinant Human Antithrombin	Disseminated Intravascular Coagulation, Congenital Antithrombin Deficiency	Phase I in EU	In-House	



 Updated since Apr 21st, 2015 (Area, Stage, Filed, Approved, etc.)  
 New Molecular Entity

Updated since Apr 21st, 2015 (Area, Stage, Filed, Approved, etc.)


Filed · Approved

Area		Code Name Generic Name Formulation	Mechanism of Action	Indication	Stage	In-House or Licensed	Remarks
Other		©KW-3357 Antithrombin Gamma Injection	Recombinant Human Antithrombin	Disseminated Intravascular Coagulation, Congenital Antithrombin Deficiency	Approved in JP	In-House	
		AMG531 Romiplostim Injection	Thrombopoietin Receptor Agonist	Idiopathic (Immune) Thrombocytopenic Purpura	Approved in TW and HK Filed in KR	Kirin-Amgen	



Ph II~Ph III

Area		Code Name Generic Name Formulation	Mechanism of Action	Indication	Stage	In-House or Licensed	Remarks
Immunology/ Allergy		©KHK4563 Benralizumab Injection	Anti-IL-5 Receptor Humanized Antibody	Chronic Obstructive Pulmonary Disease(COPD)	Phase III in JP	In-House	Jointly Developed with AstraZeneca/MedImmune in JP POTELLIGENT®
Other		©KRN23 Injection	Anti-FGF23 Fully Human Antibody	Tumor Induced Osteomalacia(TIO)/Epider- mal Nevus Syndrome (ENS)	Phase II in US	In-House	Jointly Developed with Ultragenyx KM mouse

Ph I

Area		Code Name Generic Name Formulation	Mechanism of Action	Indication	Stage	In-House or Licensed	Remarks
Oncology		KW-0761 Mogamulizumab Injection	Anti-CCR4 Humanized Antibody	Solid Tumor	Phase I in US  Phase I in JP	In-House	Combination with PF- 05082566 (Jointly Developed with Pfizer) POTELLIGENT® Combination with nivolumab (Jointly Developed with Ono Pharmaceutical / Bristol-Myers Squibb) POTELLIGENT®

Terminated

Area		Code Name Generic Name Formulation	Mechanism of Action	Indication	Stage	In-House or Licensed	Remarks
Immunology/ Allergy		©KHK4577 Oral	Anti-inflammatory Agent	Atopic Dermatitis	Phase II in JP	In-House	
		KW-0761 Mogamulizumab Injection	Anti-CCR4 Humanized Antibody	Asthma	Phase I in JP	In-House	POTELLIGENT®

## &lt;Appendix&gt; Pipeline of Biosimilar (Fujifilm Kyowa Kirin Biologics)

**Phase III**

As of July 24th 2015

Code Name	Generic Name	Stage	Remarks
FKB327	Adalimumab (fully human anti-TNF- $\alpha$ monoclonal antibody)	Phase III in US and others	

**Phase I**

Code Name	Generic Name	Stage	Remarks
FKB238	Bevacizumab (humanized anti-VEGF monoclonal antibody)	Phase I in UK	